This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	IL-3 receptor- α (CD123)	<p>Studies in mice and in cell culture suggest that antagonizing CD123 could help lower AML risk in patients with Fanconi anemia, an inherited disorder that predisposes individuals to AML and other cancers. Mice transplanted with CD123⁺ Fanconi anemia AML cells developed leukemia, whereas those receiving CD123⁻ cells did not. In CD123⁺ Fanconi anemia AML cells, a CD123-neutralizing antibody increased apoptosis compared with a control antibody. Next steps include evaluating a CD123-neutralizing antibody in a humanized mouse model.</p> <p>SciBX 4(10); doi:10.1038/scibx.2011.274 Published online March 10, 2011</p>	Work unpatented; unavailable for licensing	<p>Du, W. <i>et al. Blood</i>; published online Feb. 17, 2011; doi:10.1182/blood-2010-09-309179 Contact: Qishen Pang, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio e-mail: qishen.pang@cchmc.org</p>